Author

Alexa Buffa

Observed name: A. Buffa

Institutions: Agenus (United States), MiNK Therapeutics (United States)

Observed institutions: Agenus (United States), MiNK Therapeutics (United States)

ORCID: 0009-0007-4982-7788

Observed ORCID: 0009-0007-4982-7788

OpenAlex ID: A5090482599

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

2024 · Terese C. Hammond, Marco A. Purbhoo, et al. · Nature Communications · 48

Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors

2023 · Benedito Carneiro, Benjamin Garmezy, et al. · Cancer Research · 13

647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma

2022 · Don Stevens, Clifton Mo, et al. · Journal for ImmunoTherapy of Cancer · 4

Full-Risk Population Health Programs for Older Adults Like PACE Benefit from COVID-19

2020 · Richard Stefanacci, Alexa Buffa · Population Health Management · 4

649 Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19)

2022 · Marco Purbhoo, Burcu Yigit, et al. · Journal for ImmunoTherapy of Cancer · 3

Safe Administration of Novel Allogeneic iNKT Cell Infusion to Four Patients With Severe COVID-19 Respiratory Failure (CARDS) Receiving Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support

2023 · T.C. Hammond, M.A. Purbhoo, et al. · American Journal of Respiratory and Critical Care Medicine

Works count: 6

Citation count: 72

H-index: 4

I10-index: 2